PATH, an international nonprofit health organization, led decisions related to manufacturing, market development, and advocacy. Through PATH’s country program offices in China and South Africa, PATH staff worked directly with country partners on market research, market tests of uptake and acceptability, and advocacy to raise awareness for female condoms in general, and for the Woman’s Condom specifically.
Shanghai Dahua Medical Apparatus Co., Ltd. (DAHUA) in China led Woman’s Condom manufacturing production scale-up activities. They also led market development activities for the private sector in China. PATH licensed the Woman’s Condom to DAHUA for manufacturing and commercialization.
CONRAD is a United States—based nonprofit organization that facilitates rapid development of safe, acceptable, affordable products for contraception, HIV, and other sexually transmitted infections. CONRAD is the regulatory sponsor of the Woman’s Condom and developed and implemented the clinical study, A Randomized Cross-Over Study of Vaginal Semen Exposure and Clinical Failure Comparing the PATH Woman’s Condom and the FC2 Female Condom. This study was funded directly from the United States Agency for International Development (USAID) to CONRAD.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is a health research agency within the US government. NICHD conducts and supports clinical trials and other types of research that explore health and the process of human development from conception to old age. NICHD developed and implemented the clinical study, A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman’s Condom. Data from this study will become part of the Woman’s Condom technical dossier and will assist in regulatory submissions. This study was funded directly by the US government through NICHD.